Evidence map›Paper›PMID 41307131›Full record

ArticleHaematologica2026

Cumulative incidence and factors associated with subsequent myeloid neoplasms in patients with nodal T-follicular helper cell lymphomas.

Kai Shiang Lin, Mingfei Yan, Nivetha Ganesan, Tiffany Chang, Ahmet Dogan, Zachary Epstein-Peterson, Ozgur Can Eren, Paola Ghione, Varun Iyengar, William Johnson and 6 more

Abstract read
In one paragraph

Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. A renaissance in targeting the PI3K/AKT/mTOR pathway.Nature reviews. Drug discovery · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kai Shiang LinLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Mingfei YanHematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Nivetha GanesanLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Tiffany ChangLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Ahmet DoganHematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Zachary Epstein-PetersonLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Ozgur Can ErenHematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Paola GhioneLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Varun IyengarLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
William JohnsonLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Katie KsanznakLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Alison MoskowitzLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Benedetta SordiLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Steven HorwitzLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Wenbin XiaoHematopathology Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
Robert StuverLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA. stuverr@mskcc.org.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
The Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Eytan Stein · 2021 to 2026
$16.8M
Assessing lineage infidelity, oncogenic cooperativity and dependency in RUNX1-mutant acute myeloid leukemiaK08CA267058 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI XIAO, WENBIN · 2022 to 2025
$1.1M
NCI NIH HHS K08 CA267058NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA254838
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41307131
PMCPMC13482256

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.